JBIO
Jade Biosciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
JBIO Profile
Jade Biosciences, Inc.
A biotechnology company dedicated to developing transformative therapies for autoimmune diseases
Pharmaceutical
Invalid Date
06/30/2021
NASDAQ Stock Exchange
4
12-31
Common stock
930 Winter Street, Suite M-500, Waltham, MA 02451
--
Jade Biosciences, Inc., a Delaware company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets cytokine anti-A Proliferation-induced Ligand (APRIL) in immunoglobulin A (IGA) nephropathy, is conducting investigational new drug application enabling studies, and is expected to initiate the first human trial in the second half of 2025. Jade's pipeline also includes two undisclosed antibody discovery projects, JADE-002 and JADE-003, which are currently in preclinical development.